2. Academic Validation
  3. GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape

GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape

  • Neoplasia. 2025 Nov:69:101232. doi: 10.1016/j.neo.2025.101232.
Doudou Jing 1,  Binghong Chen 1,  Ruqi Liang 2,  Fei Li 1,  Bin Zhao 1,  Feifei Pu 3,  Wei Wu 4
Affiliations

Affiliations

  • 1 Department of Orthopaedics, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, China.
  • 2 College of Chemistry and Chemical Engineering, Taiyuan University of Technology, Taiyuan 030002, China.
  • 3 Department of Orthopaedics, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Department of Orthopaedics, Wuhan No.1 Hospital, Wuhan 430022, China. Electronic address: pufeifei@hust.edu.cn.
  • 4 Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: waynewu@hust.edu.cn.
PMID: 40975978 DOI: 10.1016/j.neo.2025.101232
Abstract

Osteosarcoma is a common malignant bone tumor, characterized by its high invasiveness and propensity for lung metastasis. Despite advances in treatment, clinical outcomes remain poor, and patient prognosis is still unsatisfactory. Therefore, the development of more effective therapies is urgently needed. Here, we demonstrate that differential expression of GBP1 significantly influences PD-L1 expression and mediates immune escape in osteosarcoma. Specifically, our results reveal that GBP1 regulates PD-L1 expression by activating CDK9 and promoting STAT3 phosphorylation. These findings suggest that targeting GBP1 may represent a promising therapeutic strategy for the treatment of osteosarcoma by impairing tumor immune evasion.

Keywords

Cancer immunotherapy; Immune escape; Osteosarcoma; PD-L1.

Figures
Products